Daiichi Sankyo

By jpalfreyman on
Expanded Access Listings

Medical Access Program for Patritumab Deruxtecan

Conditions
Epidermal Growth Factor Receptor (EGFR)-Mutated Non Small Cell Lung Cancer

The purpose of this Medical Access Program is to provide access to HER3-DXd for eligiblepatients with NSCLC who, in their treating physician's opinion, have an unmet clinicalneed which cannot be treated with approved and commercially available drugs and whocannot enter a clinical trial prior to commercial availability.

Tax Foundation: Opportunities to Reform the Food and Drug Administration’s Center for Tobacco Products

In 2022, the FDA requested the Reagan Udall Foundation conduct an independent investigation of the CTP. The resulting report highlighted several shortcomings, including a lack of a clear regulatory and product approval framework, an inefficient and slow product review process, a lack of transparency and communication, and broad struggles with the vaping market.
Coverage
Subscribe to